ALD-301: Phase II started

Cytomedix disclosed in its 4Q12 earnings that it began a double-blind, placebo-controlled,

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE